SCHEMBL1542485

SCHEMBL1542485

COc1c(/C=C/c2ccncc2C#N)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.56
MAPK14 Q16539 3/20 0.34
MCL1 Q07820 1/20 0.32
SLC22A12 Q96S37 1/20 0.32
KDR P35968 2/20 0.31
FLT3 P36888 2/20 0.31
GSK3B P49841 2/20 0.31
PRKCQ Q04759 4/20 0.31
PRKCD Q05655 1/20 0.31
PDE3B Q13370 2/20 0.31
PDE3A Q14432 2/20 0.31
KDM4E B2RXH2 1/20 0.31
PDE5A O76074 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
PTGS1 P23219 1/20 0.31
PDE4A P27815 1/20 0.31
CYP2C19 P33261 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128630 1.00 CYP3A4 (0.56) CYP3A4MAPK14MCL1SLC22A12KDR
SCHEMBL1543881 0.88 CYP3A4 (0.61) CYP3A4MAPK14MCL1PDE3BPDE3A
SCHEMBL1543883 0.88 CYP3A4 (0.61) CYP3A4MAPK14MCL1PDE3BPDE3A
SCHEMBL1542798 0.84 CYP3A4 (0.70) CYP3A4PDE3AKDM4ELMNAHPGD
SCHEMBL1542800 0.84 CYP3A4 (0.70) CYP3A4PDE3AKDM4ELMNAHPGD
SCHEMBL12678795 0.81 CYP3A4 (0.66) CYP3A4LMNAABL1
SCHEMBL2128220 0.80 CYP3A4 (0.76) CYP3A4SLC22A12
SCHEMBL2128218 0.80 CYP3A4 (0.76) CYP3A4SLC22A12
SCHEMBL1543343 0.79 CYP3A4 (0.61) CYP3A4KDRFLT3GSK3BKDM4E
SCHEMBL1543341 0.79 CYP3A4 (0.61) CYP3A4KDRFLT3GSK3BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885MAPK14 3995/4885MCL1 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.